Animal Sedative Market Size, Share, Opportunities, And Trends By Drug Class (Phenothiazines, Benzodiazepines, Alpha-2 adrenergic Receptor Agonists, Butyrophenones, Others), By Animal Type (Small, Large), By Route of Administration (Parenteral, Oral), By Application (Surgical, Diagnosis, Clinical Research Studies), And By Geography - Forecasts From 2024 To 2029

The animal sedative market is anticipated to expand at a high CAGR over the forecast period.

Rising pet ownership rates, growing concern for animal welfare, and developments in veterinary care are driving the market for animal sedatives. In veterinary medicine, sedatives are essential tools for operations like surgery, exams, and patient transportation. Pharmaceutical companies are creating a range of sedatives that are more effective and safer for various animal species. In addition, the need for sedatives in both clinical and agricultural settings is driven by the rising demand for livestock and companion animals. Innovation and changing consumer tastes are driving the global market for animal sedatives, which is growing despite regulatory obstacles and side effect concerns.

Market Drivers:

• Rising pet ownership is anticipated to boost the animal sedative market.

The growing global trend of pet ownership is driving the animal sedative industry expansion. The need for veterinary services, especially sedatives for operations like medical tests, grooming, and travel, increases in tandem with the number of people adding pets to their homes. Pet owners place a high priority on the welfare of their animals, looking for compassionate and stress-free veterinary visits.

Effective sedatives are necessary to provide safe and comfortable operations for pets as a result of the increased awareness of animal welfare. To meet this demand, pharmaceutical companies create novel sedative formulations that are suited to different animal species, which promotes market growth and evolution.

In November 2023, Adopt a Pet and Zoetis, two of the biggest names in the pet business in the United States, are collaborating to provide better access to treatment for animals in shelters and to distribute instructional materials to veterinary healthcare teams and pet owners nationwide.

• Developments in veterinary medicine are expected to boost the animal sedative market.

Developments in veterinary medicine play a major role in driving the animal sedatives market. Constant research and development activities result in the manufacture of sedatives that are safer and more effective for a variety of animal species. With the least amount of stress and discomfort for the animals, veterinarians can now execute a wide range of procedures, from simple inspections to intricate surgery.

Innovations in sedative delivery methods also improve efficacy and ease, propelling market expansion. The need for sophisticated sedatives is growing as veterinary procedures change to reduce procedural stress and prioritize animal well-being, solidifying the important role these drugs play in contemporary veterinary treatment.

In June 2023, Zoetis Inc. announced that the FDA had authorized Apoquel® Chewable, an oclacitinib chewable tablet, for the treatment of atopic dermatitis and pruritus associated with allergic dermatitis in dogs who are at least 12 months old. It is anticipated that Apoquel Chewable, the first and only chewable treatment for the management of allergic itch and inflammation in dogs, will be as effective as the original Apoquel (oclacitinib tablet) after the first dose due to a formulation that may enhance medication compliance and subsequently improve outcomes for dogs.

• Technological advancements are anticipated to boost the animal sedative market.

Innovation in the animal sedative industry is being propelled by technological developments, which are creating safer, more efficient sedatives and delivery systems. When giving sedatives to animals, new pharmacological formulations such as transdermal patches or sustained-release formulations are more convenient and effective. Furthermore, improvements in diagnostic imaging methods allow vets to precisely determine an animal's status and modify sedation protocols accordingly. Digital health platforms also make customized treatment plans and remote monitoring possible, which raises the standard of veterinary care overall. In addition to improving patient outcomes, these technical advancements have aided in the expansion and development of the worldwide market for animal sedatives.

In July 2022, Zenalpha® (medetomidine and vatinoxan hydrochlorides injection), a novel alpha-2 combination medication, is now available from Dechra. It is intended to help with clinical evaluations, minor surgical procedures, and pain management in dogs. The unique balance of central and peripheral activity produced by the combination of the alpha-2 agonist medetomidine and vatinoxan, an alpha-2 antagonist that acts peripherally without bridging the blood-brain barrier, results in less severe cardiovascular side effects while retaining the sedative and analgesic qualities of medetomidine. The first sedative with this special blend of potent medicinal substances and effects is called Zenalpha.

Asia Pacific region is expected to grow significantly.

The market for animal sedatives is growing significantly in the Asia-Pacific region due to factors such as rising pet ownership, growing concern for animal welfare, and developing veterinary healthcare facilities. The need for sedatives for various veterinary procedures is fuelled by the increased demand for companion animals, especially in metropolitan areas. Sedatives are also needed for medical treatments and management procedures in the rapidly expanding cattle industry. More market expansion is made possible by technological developments and regulatory assistance, which also make it easier to create and implement safer and more effective sedatives that are suited to different animal species and regional preferences. All these factors work together to drive the animal sedative market growth in the Asia-Pacific region.

Market Restraints:

• Ensuring safety and efficacy can constrain the market for animal sedatives.

Ensuring safety and efficacy across a range of animal species and sizes is a significant challenge in the animal sedative business. It is difficult to create formulations that are consistently successful since animals differ greatly in their physiology, metabolism, and reaction to sedatives. Additionally, cautious dosage adjustment and monitoring are required due to concerns about possible adverse effects, such as respiratory depression and extended recovery times. To maintain the well-being of animals, addressing these issues calls for intensive research, cooperation between pharmaceutical companies and veterinarians, and adherence to strict regulatory standards.

Market Development:

• October 2023 - According to Zoetis, LibrelaTM will soon be available for purchase in the United States, highlighting the company's cutting-edge leadership in canine innovation and commitment to offering customized care to meet dogs' medical needs. On May 5, 2023, the FDA in the United States authorized Librela, an injectable monoclonal antibody, once monthly to treat osteoarthritis-related pain in dogs. This treatment helps dogs with OA pain feel more mobile and have a higher quality of life.
• July 2022 - Zimeta® has been acquired by Dechra from Elanco® Animal Health. The first and only medication for treating pyrexia in horses that has received FDA approval is Zimeta. now January 2021, Dechra has been selling Zimeta in the US, and it has now obtained the registrations. There won't be any changes made to the way veterinary clients order the goods.

Market Segmentation:

• By Drug Class
  • Phenothiazines
  • Benzodiazepines
  • Alpha-2 adrenergic Receptor Agonists
  • Butyrophenones
  • Others
• By Animal Type
  • Small
  • Large
• By Route of Administration
  • Parenteral
  • Oral
• By Application
  • Surgical
  • Diagnosis
  • Clinical Research Studies
• By Geography:
  • North America
    • United States
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Others
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Taiwan
    • Thailand
    • Indonesia
    • Others

1. INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline

1.8. Key Benefits for the stakeholder

2. RESEARCH METHODOLOGY  

2.1. Research Design

2.2. Research Processes

3. EXECUTIVE SUMMARY

3.1. Key Findings

3.2. Analyst View

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Forces Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

4.5. Analyst View

5. ANIMAL SEDATIVE MARKET BY DRUG CLASS

5.1. Introduction

5.2. Phenothiazines

5.2.1. Market Trends and Opportunities

5.2.2. Growth Prospects

5.3. Benzodiazepines

5.3.1. Market Trends and Opportunities

5.3.2. Growth Prospects

5.4. Alpha-2 adrenergic Receptor Agonists

5.4.1. Market Trends and Opportunities

5.4.2. Growth Prospects

5.5. Butyrophenones 

5.5.1. Market Trends and Opportunities

5.5.2. Growth Prospects

5.6. Others

5.6.1. Market Trends and Opportunities

5.6.2. Growth Prospects

6. ANIMAL SEDATIVE MARKET BY ANIMAL TYPE 

6.1. Introduction

6.2. Small

6.2.1. Market Trends and Opportunities

6.2.2. Growth Prospects

6.3. Large

6.3.1. Market Trends and Opportunities

6.3.2. Growth Prospects

7. ANIMAL SEDATIVE MARKET BY ROUTE OF ADMINISTRATION 

7.1. Introduction

7.2. Parenteral

7.2.1. Market Trends and Opportunities

7.2.2. Growth Prospects

7.3. Oral

7.3.1. Market Trends and Opportunities

7.3.2. Growth Prospects

8. ANIMAL SEDATIVE MARKET BY APPLICATION

8.1. Introduction

8.2. Surgical  

8.2.1. Market Trends and Opportunities

8.2.2. Growth Prospects

8.3. Diagnosis   

8.3.1. Market Trends and Opportunities

8.3.2. Growth Prospects

8.4. Clinical Research Studies 

8.4.1. Market Trends and Opportunities

8.4.2. Growth Prospects

9. ANIMAL SEDATIVE MARKET BY GEOGRAPHY

9.1. Introduction

9.2. North America

9.2.1. By Drug Class

9.2.2. By Animal Type

9.2.3. By Route of Administration

9.2.4. By Application

9.2.5. By Country

9.2.5.1. United States

9.2.5.1.1. Market Trends and Opportunities

9.2.5.1.2. Growth Prospects

9.2.5.2. Canada

9.2.5.2.1. Market Trends and Opportunities

9.2.5.2.2. Growth Prospects

9.2.5.3. Mexico

9.2.5.3.1. Market Trends and Opportunities

9.2.5.3.2. Growth Prospects

9.3. South America

9.3.1. By Drug Class

9.3.2. By Animal Type

9.3.3. By Route of Administration

9.3.4. By Application

9.3.5. By Country 

9.3.5.1. Brazil

9.3.5.1.1. Market Trends and Opportunities

9.3.5.1.2. Growth Prospects

9.3.5.2. Argentina

9.3.5.2.1. Market Trends and Opportunities

9.3.5.2.2. Growth Prospects

9.3.5.3. Others

9.3.5.3.1. Market Trends and Opportunities

9.3.5.3.2. Growth Prospects

9.4. Europe

9.4.1. By Drug Class

9.4.2. By Animal Type

9.4.3. By Route of Administration

9.4.4. By Application

9.4.5. By Country

9.4.5.1. United Kingdom

9.4.5.1.1. Market Trends and Opportunities

9.4.5.1.2. Growth Prospects

9.4.5.2. Germany

9.4.5.2.1. Market Trends and Opportunities

9.4.5.2.2. Growth Prospects

9.4.5.3. France

9.4.5.3.1. Market Trends and Opportunities

9.4.5.3.2. Growth Prospects

9.4.5.4. Italy

9.4.5.4.1. Market Trends and Opportunities

9.4.5.4.2. Growth Prospects

9.4.5.5. Spain

9.4.5.5.1. Market Trends and Opportunities

9.4.5.5.2. Growth Prospects

9.4.5.6. Others

9.4.5.6.1. Market Trends and Opportunities

9.4.5.6.2. Growth Prospects

9.5. Middle East and Africa

9.5.1. By Drug Class

9.5.2. By Animal Type

9.5.3. By Route of Administration

9.5.4. By Application

9.5.5. By Country

9.5.5.1. Saudi Arabia

9.5.5.1.1. Market Trends and Opportunities

9.5.5.1.2. Growth Prospects

9.5.5.2. UAE

9.5.5.2.1. Market Trends and Opportunities

9.5.5.2.2. Growth Prospects

9.5.5.3. Others

9.5.5.3.1. Market Trends and Opportunities

9.5.5.3.2. Growth Prospects

9.6. Asia Pacific

9.6.1. By Drug Class

9.6.2. By Animal Type

9.6.3. By Route of Administration

9.6.4. By Application

9.6.5. By Country

9.6.5.1. Japan

9.6.5.1.1. Market Trends and Opportunities

9.6.5.1.2. Growth Prospects

9.6.5.2. China

9.6.5.2.1. Market Trends and Opportunities

9.6.5.2.2. Growth Prospects

9.6.5.3. India

9.6.5.3.1. Market Trends and Opportunities

9.6.5.3.2. Growth Prospects

9.6.5.4. South Korea

9.6.5.4.1. Market Trends and Opportunities

9.6.5.4.2. Growth Prospects

9.6.5.5. Taiwan

9.6.5.5.1. Market Trends and Opportunities

9.6.5.5.2. Growth Prospects

9.6.5.6. Thailand

9.6.5.6.1. Market Trends and Opportunities

9.6.5.6.2. Growth Prospects

9.6.5.7. Indonesia

9.6.5.7.1. Market Trends and Opportunities

9.6.5.7.2. Growth Prospects

9.6.5.8. Others

9.6.5.8.1. Market Trends and Opportunities

9.6.5.8.2. Growth Prospects

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

10.1. Major Players and Strategy Analysis

10.2. Market Share Analysis

10.3. Mergers, Acquisitions, Agreements, and Collaborations

10.4. Competitive Dashboard

11. COMPANY PROFILES

11.1. Zoetis Inc.

11.2. Boehringer Ingelheim International GmbH

11.3. Merck & Co. Inc.

11.4. Elanco

11.5. Virbac Group

11.6. Dechra Pharmaceuticals PLC

11.7. Orion Corporation

11.8. Vetoquinol

11.9.  Ceva 

Zoetis Inc.

Boehringer Ingelheim International GmbH

Merck & Co. Inc.

Elanco

Virbac Group

Dechra Pharmaceuticals PLC

Orion Corporation

Vetoquinol

 Ceva